349 related articles for article (PubMed ID: 11835024)
1. Bivalirudin as a replacement for unfractionated heparin in unstable angina/non-ST-elevation myocardial infarction: observations from the TIMI 8 trial. The Thrombolysis in Myocardial Infarction.
Antman EM; McCabe CH; Braunwald E
Am Heart J; 2002 Feb; 143(2):229-34. PubMed ID: 11835024
[TBL] [Abstract][Full Text] [Related]
2. Abciximab and heparin versus bivalirudin for non-ST-elevation myocardial infarction.
Kastrati A; Neumann FJ; Schulz S; Massberg S; Byrne RA; Ferenc M; Laugwitz KL; Pache J; Ott I; Hausleiter J; Seyfarth M; Gick M; Antoniucci D; Schömig A; Berger PB; Mehilli J;
N Engl J Med; 2011 Nov; 365(21):1980-9. PubMed ID: 22077909
[TBL] [Abstract][Full Text] [Related]
3. Bivalirudin: a review of its potential place in the management of acute coronary syndromes.
Carswell CI; Plosker GL
Drugs; 2002; 62(5):841-70. PubMed ID: 11929334
[TBL] [Abstract][Full Text] [Related]
4. Bivalirudin versus unfractionated heparin during percutaneous coronary intervention.
Kastrati A; Neumann FJ; Mehilli J; Byrne RA; Iijima R; Büttner HJ; Khattab AA; Schulz S; Blankenship JC; Pache J; Minners J; Seyfarth M; Graf I; Skelding KA; Dirschinger J; Richardt G; Berger PB; Schömig A;
N Engl J Med; 2008 Aug; 359(7):688-96. PubMed ID: 18703471
[TBL] [Abstract][Full Text] [Related]
5. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the HERO-2 randomised trial.
White H;
Lancet; 2001 Dec; 358(9296):1855-63. PubMed ID: 11741625
[TBL] [Abstract][Full Text] [Related]
6. Bivalirudin: a direct thrombin inhibitor.
Gladwell TD
Clin Ther; 2002 Jan; 24(1):38-58. PubMed ID: 11833835
[TBL] [Abstract][Full Text] [Related]
7. Bivalirudin versus heparin plus a glycoprotein IIb/IIIa inhibitor in patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention after clopidogrel pretreatment: pooled analysis from the ACUITY and ISAR-REACT 4 trials.
Ndrepepa G; Neumann FJ; Deliargyris EN; Mehran R; Mehilli J; Ferenc M; Schulz S; Schömig A; Kastrati A; Stone GW
Circ Cardiovasc Interv; 2012 Oct; 5(5):705-12. PubMed ID: 23048052
[TBL] [Abstract][Full Text] [Related]
8. One-year outcomes with abciximab and unfractionated heparin versus bivalirudin during percutaneous coronary interventions in patients with non-ST-segment elevation myocardial infarction: updated results from the ISAR-REACT 4 trial.
Schulz S; Kastrati A; Ferenc M; Massberg S; Birkmeier KA; Laugwitz KL; Kufner S; Gick M; Dommasch M; Schühlen H; Schömig A; Berger PB; Mehilli J; Neumann FJ;
EuroIntervention; 2013 Aug; 9(4):430-6. PubMed ID: 23455033
[TBL] [Abstract][Full Text] [Related]
9. Sex-related response to bivalirudin and unfractionated heparin in patients with acute myocardial infarction undergoing percutaneous coronary intervention: A subgroup analysis of the VALIDATE-SWEDEHEART trial.
Venetsanos D; Sederholm Lawesson S; Fröbert O; Omerovic E; Henareh L; Robertsson L; Linder R; Götberg M; James S; Alfredsson J; Erlinge D; Swahn E
Eur Heart J Acute Cardiovasc Care; 2019 Sep; 8(6):502-509. PubMed ID: 30351167
[TBL] [Abstract][Full Text] [Related]
10. Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors.
Bangalore S; Toklu B; Kotwal A; Volodarskiy A; Sharma S; Kirtane AJ; Feit F
BMJ; 2014 Nov; 349():g6419. PubMed ID: 25389143
[TBL] [Abstract][Full Text] [Related]
11. Bivalirudin for primary percutaneous coronary interventions: outcome assessment in the Ottawa STEMI registry.
Hibbert B; MacDougall A; Labinaz M; O'Brien ER; So DY; Dick A; Glover C; Froeschl M; Marquis JF; Wells GA; Blondeau M; Le May MR
Circ Cardiovasc Interv; 2012 Dec; 5(6):805-12. PubMed ID: 23149331
[TBL] [Abstract][Full Text] [Related]
12. Bivalirudin during primary PCI in acute myocardial infarction.
Stone GW; Witzenbichler B; Guagliumi G; Peruga JZ; Brodie BR; Dudek D; Kornowski R; Hartmann F; Gersh BJ; Pocock SJ; Dangas G; Wong SC; Kirtane AJ; Parise H; Mehran R;
N Engl J Med; 2008 May; 358(21):2218-30. PubMed ID: 18499566
[TBL] [Abstract][Full Text] [Related]
13. Bivalirudin Versus Heparin Monotherapy in Elderly Patients With Myocardial Infarction: A Prespecified Subgroup Analysis of the VALIDATE-SWEDEHEART Trial.
Wester A; Attar R; Mohammad MA; Isma N; James S; Omerovic E; Erlinge D; Koul S
Circ Cardiovasc Interv; 2020 Apr; 13(4):e008671. PubMed ID: 32216471
[TBL] [Abstract][Full Text] [Related]
14. Lack of clopidogrel pretreatment effect on the relative efficacy of bivalirudin with provisional glycoprotein IIb/IIIa blockade compared to heparin with routine glycoprotein IIb/IIIa blockade: a REPLACE-2 substudy.
Saw J; Lincoff AM; DeSmet W; Betriu A; Rutsch W; Wilcox RG; Kleiman NS; Wolski K; Topol EJ;
J Am Coll Cardiol; 2004 Sep; 44(6):1194-9. PubMed ID: 15364319
[TBL] [Abstract][Full Text] [Related]
15. Randomized, double-blind comparison of hirulog versus heparin in patients receiving streptokinase and aspirin for acute myocardial infarction (HERO). Hirulog Early Reperfusion/Occlusion (HERO) Trial Investigators.
White HD; Aylward PE; Frey MJ; Adgey AA; Nair R; Hillis WS; Shalev Y; Brown MA; French JK; Collins R; Maraganore J; Adelman B
Circulation; 1997 Oct; 96(7):2155-61. PubMed ID: 9337184
[TBL] [Abstract][Full Text] [Related]
16. Improved efficacy and less bleeding: further evidence of a unique uncoupling of benefit and risk with bivalirudin.
White HD
Am Heart J; 2002 Feb; 143(2):189-92. PubMed ID: 11835018
[No Abstract] [Full Text] [Related]
17. Radial versus femoral access and bivalirudin versus unfractionated heparin in invasively managed patients with acute coronary syndrome (MATRIX): final 1-year results of a multicentre, randomised controlled trial.
Valgimigli M; Frigoli E; Leonardi S; Vranckx P; Rothenbühler M; Tebaldi M; Varbella F; Calabrò P; Garducci S; Rubartelli P; Briguori C; Andó G; Ferrario M; Limbruno U; Garbo R; Sganzerla P; Russo F; Nazzaro M; Lupi A; Cortese B; Ausiello A; Ierna S; Esposito G; Ferrante G; Santarelli A; Sardella G; de Cesare N; Tosi P; van 't Hof A; Omerovic E; Brugaletta S; Windecker S; Heg D; Jüni P;
Lancet; 2018 Sep; 392(10150):835-848. PubMed ID: 30153988
[TBL] [Abstract][Full Text] [Related]
18. Use and Effectiveness of Bivalirudin Versus Unfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States.
Secemsky EA; Kirtane A; Bangalore S; Jovin IS; Shah RM; Ferro EG; Wimmer NJ; Roe M; Dai D; Mauri L; Yeh RW
JACC Cardiovasc Interv; 2016 Dec; 9(23):2376-2386. PubMed ID: 27838271
[TBL] [Abstract][Full Text] [Related]
19. Effect of bivalirudin compared with unfractionated heparin plus abciximab on infarct size and myocardial recovery after primary percutaneous coronary intervention: the horizons-AMI CMRI substudy.
Wöhrle J; Merkle N; Kunze M; Cristea E; Mehran R; Rottbauer W; Stone GW
Catheter Cardiovasc Interv; 2012 Jun; 79(7):1083-9. PubMed ID: 22162175
[TBL] [Abstract][Full Text] [Related]
20. Sex-based differences in outcomes with bivalirudin or unfractionated heparin for transcatheter aortic valve replacement: Results from the BRAVO-3 randomized trial.
Asgar A; Chandrasekhar J; Mikhail G; Webb J; Lefèvre T; Tamburino C; Hildick-Smith D; Hambrecht R; Van Belle E; Widder J; Dumonteil N; Hink U; Jeger R; Linke A; Deliargyris E; Gao P; Mehran R; Hengstenberg C; Anthopoulos P; Dangas G;
Catheter Cardiovasc Interv; 2017 Jan; 89(1):144-153. PubMed ID: 27152677
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]